Biomedical and Pharma

<h1>Biomedical and Pharma</h1> <p>Singapore's biomedical sciences (BMS) sector is a state-built pillar of advanced manufacturing, spanning biopharmaceutical production, medical technology, and the research infrastructure that feeds both. The sector is promoted by the <a href="/en/knowledge/article/sgkb.business-industry.doing-business">Singapore Economic Development Board</a> (EDB) and regulated for drug manufacturing by the Health Sciences Authority (HSA). As of 2024, biopharmaceutical and medical-technology activity contributed about 1.9% of Singapore's GDP — the GDP denominator is Singapore's whole economy — and produced more than S$32 billion worth of products for global markets; that product value is an industry-output measure, not domestic healthcare spending (<a href="https://www.edb.gov.sg/en/business-insights/insights/singapores-rise-as-a-biomedical-sciences-powerhouse-the-talent-driving-its-next-chapter.html">EDB, accessed Aug 2026</a>). Singapore hosts more than 60 BMS manufacturing plants, over 30 research and development centres, and more than 80 regional headquarters, including eight of the world's top 10 biopharmaceutical companies by the government's count as of May 2026; the dated scale and output anchors are tabulated in <a href="/en/knowledge/dataset/sgkb.data.biomedical-pharma-anchors">biomedical pharma anchors</a> (<a href="https://www.mti.gov.sg/newsroom/written-reply-to-pq-on-assessing-biomedical-sectors-resilience-and-recalibrating-singapore-s-long-term-economic-strategy-and-retain-mnc-manufacturers/">MTI, accessed Aug 2026</a>; <a href="https://www.edb.gov.sg/en/business-insights/insights/singapores-rise-as-a-biomedical-sciences-powerhouse-the-talent-driving-its-next-chapter.html">EDB, accessed Aug 2026</a>). The sector sits alongside <a href="/en/knowledge/article/sgkb.business-industry.electronics-and-semiconductors">electronics and semiconductors</a> as a high-value manufacturing cluster within Singapore's broader <a href="/en/knowledge/article/sgkb.economy-finance.economy-overview">open economy</a>.</p> <h2>Economic scale and manufacturing output</h2> <p>The biomedical sciences sector employs more than 26,000 people in Singapore as of 2024, nearly triple the headcount of two decades earlier, across manufacturing, R&amp;D, regional headquarters, and supporting functions such as quality assurance, regulatory affairs, and supply chain (<a href="https://www.edb.gov.sg/en/business-insights/insights/singapores-rise-as-a-biomedical-sciences-powerhouse-the-talent-driving-its-next-chapter.html">EDB, accessed Aug 2026</a>). Employment spans both science and engineering roles and commercial, digital, and operations positions anchored by multinationals such as GSK and ResMed.</p> <p>Within Singapore's manufacturing statistics, biomedical manufacturing is tracked as its own cluster, split into pharmaceuticals and medical technology. In April 2026, biomedical manufacturing accounted for 11.3% of total manufacturing output on an index basis (2025 = 100), with pharmaceuticals at 3.7% and medical technology at 7.6% (<a href="https://www.edb.gov.sg/en/about-edb/media-releases-publications/monthly-manufacturing-performance.html">EDB Monthly Manufacturing Performance</a>). The cluster is cyclical and product-specific: biomedical output fell 16.1% year-on-year in April 2026 on softer medical-device demand and lower biologics production, even as the rest of manufacturing grew strongly (<a href="https://www.edb.gov.sg/en/about-edb/media-releases-publications/monthly-manufacturing-performance.html">EDB Monthly Manufacturing Performance</a>). Conversely, the biomedical manufacturing cluster grew 45.9% year-on-year in the fourth quarter of 2025, driven by higher production of a key high-value active pharmaceutical ingredient (<a href="https://www.sgpc.gov.sg/api/file/getfile/ESS%202025_Press%20Release_embargoed%20untl%2010Feb26%20at%208am.pdf?path=%2Fsgpcmedia%2Fmedia_releases%2Fmti%2Fpress_release%2FP-20260210-1%2Fattachment%2FESS+2025+Press+Release+embargoed+untl+10Feb26+at+8am.pdf">MTI Economic Survey of Singapore 2025, accessed Aug 2026</a>). These swings illustrate that Singapore's BMS sector is an export engine tied to global drug pipelines and device demand, not a proxy for domestic <a href="/en/knowledge/article/sgkb.healthcare.healthcare-system-overview">healthcare delivery</a>.</p> <h2>How the sector was built</h2> <p>Singapore's biomedical push is a deliberate, whole-of-government industrial strategy rather than organic cluster growth. The government launched the Biomedical Sciences initiative in June 2000, selecting life sciences as a fourth manufacturing pillar and coordinating industrial development (led by EDB's Biomedical Sciences Group), strategic venture investment (through the Bio<em>One Capital fund), and public research funding (through what became A</em>STAR's Biomedical Research Council) (<a href="https://www.nas.gov.sg/archivesonline/data/pdfdoc/2003102904.htm">NAS, accessed Aug 2026</a>). The vision was to span the full value chain — from basic research through manufacturing to healthcare delivery — rather than remain a low-cost pill-pressing location.</p> <p>Biopolis, opened in October 2003 at <a href="/en/knowledge/article/sgkb.geography-urban-planning.ura-and-master-plan">one-north</a>, was conceived as the research cornerstone: a dedicated biomedical R&amp;D campus bringing public institutes and private laboratories together to create knowledge-intensive jobs (<a href="https://www.nas.gov.sg/archivesonline/data/pdfdoc/2003102904.htm">NAS, accessed Aug 2026</a>). In parallel, JTC Corporation developed Tuas Biomedical Park as the manufacturing counterpart. Foreign pharmaceutical firms had manufactured in Singapore since the 1970s, but the 2000 initiative accelerated movement up the value chain into biologics, active pharmaceutical ingredients, and regional headquarters functions. The model mirrors Singapore's broader development approach: land and infrastructure from JTC, research translation through A*STAR, investment facilitation through EDB, and internationally recognised regulatory standards through HSA.</p> <h2>Manufacturing at Tuas Biomedical Park</h2> <p>Tuas Biomedical Park (TBP) in western Singapore is the primary manufacturing estate for pharmaceuticals, biologics, and medical technology. JTC markets TBP as a plug-and-play biomedical hub with purpose-built infrastructure — power, water, sewer, gas, telecommunications, and shared utilities including steam, chilled water, and waste treatment — so companies can commission plants quickly (<a href="https://www.jtc.gov.sg/find-land/jtc-key-estates/tuas-biomedical-park">JTC, accessed Aug 2026</a>). The park comprises Tuas Biomedical Park I (about 183 hectares) and Tuas Biomedical Park II (about 188 hectares), located near the Tuas Checkpoint to Malaysia and the developing Tuas Port (<a href="https://www.jtc.gov.sg/find-land/jtc-key-estates/tuas-biomedical-park">JTC, accessed Aug 2026</a>).</p> <p>Major global biopharma manufacturers operate at TBP, including Pfizer, Novartis, GSK, Roche, and MSD among the companies cited in parliamentary replies (<a href="https://www.mti.gov.sg/newsroom/written-reply-to-pq-on-assessing-biomedical-sectors-resilience-and-recalibrating-singapore-s-long-term-economic-strategy-and-retain-mnc-manufacturers/">MTI, accessed Aug 2026</a>). GSK's vaccine production site in Tuas, for example, produces two vaccines covering approximately 45% of diseases causing paediatric mortality globally, and GSK employs about 1,600 people across its Singapore pharmaceutical and vaccine operations (<a href="https://www.jtc.gov.sg/about-jtc/news-and-stories/feature-stories/getting-the-formula-right-in-growing-local-biomedical-sector">JTC, accessed Aug 2026</a>). Manufacturing activities range from active pharmaceutical ingredients and final dosage forms (including injectables) to biologics, medical devices, and newer capabilities such as cell processing.</p> <p>JTC has also developed supporting infrastructure such as JTC BioMed Hub within TBP to cluster biomedical suppliers and SMEs, and a Biopharma Industry Council comprising government agencies and pharmaceutical companies based largely at the park to promote manufacturing excellence. Recent anchor investments include AstraZeneca's US$1.5 billion end-to-end antibody drug conjugate (ADC) manufacturing facility in Tuas South — the company's first global ADC site incorporating drug substance and drug product on one campus, targeted for operational readiness by 2029 with more than 800 jobs and net-zero emissions from day one (<a href="https://www.mti.gov.sg/newsroom/speech-by-dpm-and-minister-for-trade-and-industry-gan-kim-yong-at-astrazeneca-s-antibody-drug-conjugate--adc--manufacturing-facility-groundbreaking-ceremony/">MTI, accessed Aug 2026</a>; <a href="https://www.edb.gov.sg/en/about-edb/media-releases-publications/astrazeneca-to-hire-over-800-employees-for-antibody-drug-conjugate-facility-in-singapore.html">EDB, accessed Aug 2026</a>).</p> <h2>Research, innovation, and talent</h2> <p>Singapore's biomedical research infrastructure is concentrated at one-north, where Biopolis houses A<em>STAR biomedical research institutes alongside corporate laboratories. A</em>STAR's biomedical entities include the Bioinformatics Institute, Bioprocessing Technology Institute, Genome Institute of Singapore, Institute of Molecular and Cell Biology, Singapore Immunology Network, and others focused on areas from infectious disease to food and biotechnology (<a href="https://www.a-star.edu.sg/">A*STAR, accessed Aug 2026</a>). Biopolis was designed to co-locate public research with industry — early tenants included the Novartis Institute for Tropical Diseases and Johns Hopkins Singapore, alongside A*STAR institutes moving in from 2003 (<a href="https://www.nas.gov.sg/archivesonline/data/pdfdoc/2003102904.htm">NAS, accessed Aug 2026</a>). EDB describes one-north more broadly as hosting over 400 companies, 15 research institutes, and six institutions of higher learning as of 2025 (<a href="https://www.edb.gov.sg/en/business-insights/insights/singapores-rise-as-a-biomedical-sciences-powerhouse-the-talent-driving-its-next-chapter.html">EDB, accessed Aug 2026</a>).</p> <p>A*STAR anchors research translation — converting discoveries into applications through industry partnerships and national platforms such as the Nucleic Acid Therapeutics Initiative (<a href="https://www.edb.gov.sg/en/business-insights/insights/singapores-rise-as-a-biomedical-sciences-powerhouse-the-talent-driving-its-next-chapter.html">EDB, accessed Aug 2026</a>). EDB also runs overseas training programmes that place Singapore graduates in multinational manufacturing sites before they return to local plants. As of 2025, Singapore reported more than 53,000 researchers nationally, with around 45% of ITE, polytechnic, and university graduates coming from STEM-related courses (<a href="https://www.edb.gov.sg/en/business-insights/insights/singapores-rise-as-a-biomedical-sciences-powerhouse-the-talent-driving-its-next-chapter.html">EDB, accessed Aug 2026</a>). The sector's next growth areas — biologics, cell and gene therapies, digital health, and precision medicine — are expected to demand clinical expertise combined with data and computing skills (<a href="https://www.edb.gov.sg/en/business-insights/insights/singapores-rise-as-a-biomedical-sciences-powerhouse-the-talent-driving-its-next-chapter.html">EDB, accessed Aug 2026</a>).</p> <h2>Regulation and manufacturing standards</h2> <p>Drug manufacturing in Singapore is regulated by the Health Sciences Authority (HSA), which is distinct from the clinical <a href="/en/knowledge/article/sgkb.healthcare.healthcare-system-overview">healthcare system</a> overseen by the Ministry of Health (MOH); MOH's clinical healthcare role is separate from HSA's factory licensing role. HSA GMP licensing covers local manufacturers of therapeutic products and active ingredients, which must comply with the current Pharmaceutical Inspection Co-operation Scheme (PIC/S) Guide to Good Manufacturing Practice (GMP) — the international standard for consistent production and quality control (<a href="https://www.hsa.gov.sg/therapeutic-products/manufacturing-import-wholesale/licence-to-manufacturer-import-or-wholesale/gmp-gdp/">HSA, accessed Aug 2026</a>). Local manufacturers must pass HSA pre-approval GMP audits before receiving a manufacturer's licence; routine and unannounced audits follow (<a href="https://www.hsa.gov.sg/therapeutic-products/manufacturing-import-wholesale/licence-to-manufacturer-import-or-wholesale/apply/">HSA, accessed Aug 2026</a>). Each licensed site must appoint responsible persons for production and quality operations with relevant practical experience (<a href="https://www.hsa.gov.sg/therapeutic-products/manufacturing-import-wholesale/licence-to-manufacturer-import-or-wholesale/overview/">HSA, accessed Aug 2026</a>).</p> <p>HSA's PIC/S membership gives Singapore-manufactured drugs credibility in global supply chains: overseas regulators accept GMP evidence from PIC/S member authorities when registering products. HSA encourages companies planning new Singapore manufacturing sites to engage its GMP unit early in the design process (<a href="https://www.hsa.gov.sg/active-ingredients/manufacturers/apply-licence">HSA, accessed Aug 2026</a>). This regulatory reputation is part of Singapore's investment pitch — alongside infrastructure, talent, and intellectual-property protection — for high-value biologics and ADC production rather than commodity generics alone.</p> <h2>Strategic trade-offs and critical questions</h2> <p>The sector has two different success tests. An industrial-policy reading measures export value, fixed-asset investment, trusted regulation, high-skill jobs, and the ability to attract the next complex manufacturing platform; a domestic-benefit reading asks how far those gains strengthen local firms, research careers, resilience of essential supplies, and access to resulting medicines or devices. EDB and MTI evidence establishes the first set of outputs, but it does not by itself answer the distributional or healthcare questions in the second set (<a href="https://www.edb.gov.sg/en/business-insights/insights/singapores-rise-as-a-biomedical-sciences-powerhouse-the-talent-driving-its-next-chapter.html">EDB, accessed Aug 2026</a>; <a href="https://www.mti.gov.sg/newsroom/written-reply-to-pq-on-assessing-biomedical-sectors-resilience-and-recalibrating-singapore-s-long-term-economic-strategy-and-retain-mnc-manufacturers/">MTI, accessed Aug 2026</a>).</p> <p>There is a related resilience-versus-efficiency trade-off. Concentrating plants, suppliers, research institutions, and multinational headquarters in an integrated cluster can shorten development and manufacturing links, while dependence on global company pipelines means that a site closure or product-cycle change can affect output even when Singapore's fundamentals remain strong (<a href="https://www.jtc.gov.sg/find-land/jtc-key-estates/tuas-biomedical-park">JTC, accessed Aug 2026</a>; <a href="https://www.mti.gov.sg/newsroom/written-reply-to-pq-on-assessing-biomedical-sectors-resilience-and-recalibrating-singapore-s-long-term-economic-strategy-and-retain-mnc-manufacturers/">MTI, accessed Aug 2026</a>). HSA's GMP and licensing standards protect quality and supply-chain credibility, but compliance, land, talent, and operating costs are also part of the competitiveness equation (<a href="https://www.hsa.gov.sg/therapeutic-products/manufacturing-import-wholesale/licence-to-manufacturer-import-or-wholesale/gmp-gdp/">HSA, accessed Aug 2026</a>). These are evaluation questions rather than evidence of failure: claims about “resilience,” “local capability,” or “public value” should specify the indicator, time period, population, and denominator being used.</p> <h2>Investment outlook and sector challenges</h2> <p>EDB attracted S$4.4 billion in fixed-asset investments for the biomedical sciences sector in 2025, projected to create 1,775 jobs over five years (<a href="https://www.mti.gov.sg/newsroom/written-reply-to-pq-on-assessing-biomedical-sectors-resilience-and-recalibrating-singapore-s-long-term-economic-strategy-and-retain-mnc-manufacturers/">MTI, accessed Aug 2026</a>). The government characterises the outlook as strong, citing anchor projects such as AstraZeneca's ADC plant as evidence that Singapore continues to win complex manufacturing capabilities (<a href="https://www.mti.gov.sg/newsroom/written-reply-to-pq-on-assessing-biomedical-sectors-resilience-and-recalibrating-singapore-s-long-term-economic-strategy-and-retain-mnc-manufacturers/">MTI, accessed Aug 2026</a>).</p> <p>The sector is not without friction. Parliamentary questions in May 2026 followed announcements of local biopharma plant closures, prompting the Ministry of Trade and Industry to distinguish company-specific commercial decisions from a weakening of Singapore's overall value proposition (<a href="https://www.mti.gov.sg/newsroom/written-reply-to-pq-on-assessing-biomedical-sectors-resilience-and-recalibrating-singapore-s-long-term-economic-strategy-and-retain-mnc-manufacturers/">MTI, accessed Aug 2026</a>). Rising operating costs and improving regional workforce capabilities in competing jurisdictions add pressure. The government's response emphasises productivity, automation, artificial intelligence, and robotics adoption by existing manufacturers, alongside continued investment in fundamentals — research infrastructure, regulatory quality, and talent pipelines (<a href="https://www.mti.gov.sg/newsroom/written-reply-to-pq-on-assessing-biomedical-sectors-resilience-and-recalibrating-singapore-s-long-term-economic-strategy-and-retain-mnc-manufacturers/">MTI, accessed Aug 2026</a>). For Singapore, the biomedical sciences sector remains a bet that a city-state with no domestic market can sustain premium manufacturing by offering trusted regulation, integrated research-to-factory infrastructure, and skilled labour at the frontier of biologics and precision medicine.</p>

简介

生物医学与制药

新加坡的生物医学科学(BMS)领域是政府建设的先进制造业支柱,涵盖生物制药生产、医疗技术,以及为这两者提供支持的研究基础设施。该领域由新加坡经济发展局(EDB)推动,药品制造则由卫生科学局(HSA)监管。截至 2024 年,生物制药和医疗技术活动约占新加坡国内生产总值的 1.9%——此处的国内生产总值分母指新加坡整体经济——并为全球市场生产了价值超过 S$32 十亿新元的产品;该产品价值是行业产出指标,并非国内医疗保健支出(EDB,访问于 2026 年八月)。截至 2026 年五月,按政府统计,新加坡有 60 多家 BMS 制造厂、30 多个研发中心和 80 多个区域总部,其中包括全球 10 大生物制药公司中的 八家;按日期列出的规模和产出基准见生物医药制药基准数据(贸工部,访问于 2026 年八月;EDB,访问于 2026 年八月)。该领域与电子和半导体并列,作为新加坡更广泛开放型经济中的高价值制造业集群。

经济规模与制造业产出

截至 2024 年,新加坡的生物医学科学领域雇用超过 26,000 人,几乎是两个十年前人数的近三倍,涵盖制造、研发、区域总部,以及质量保证、法规事务和供应链等支持职能(EDB,访问于 2026 年八月)。就业岗位涵盖科学和工程职位,也包括由 GSK 和 ResMed 等跨国公司提供的商业、数字化和运营职位。

在新加坡的制造业统计中,生物医学制造业作为独立集群进行追踪,分为制药和医疗技术。2026 年四月,按指数计算(2025 = 100),生物医学制造业占制造业总产出的 11.3%,其中制药业占 3.7%,医疗技术占 7.6%(EDB 每月制造业表现)。该集群具有周期性,表现因产品而异:受医疗器械需求疲软和生物制品产量下降影响,2026 年四月生物医学产出同比下降 16.1%,同期其余制造业则实现强劲增长(EDB 每月制造业表现)。相反,受一种关键高价值活性药物成分产量增加推动,生物医学制造业集群在 2025 年第四季度同比增长 45.9%(贸工部《2025 年新加坡经济调查》,访问于 2026 年八月)。这些波动表明,新加坡的 BMS 领域是依托全球药物研发管线和器械需求的出口引擎,并不能作为国内医疗保健服务的替代指标。

该领域的建设历程

新加坡推动生物医学产业发展,是一项由政府整体规划的产业战略,而不是自然形成的产业集群增长。政府于 2000 年六月启动生物医学科学计划,将生命科学列为第四大制造业支柱,并统筹产业发展(由 EDB 生物医学科学组主导)、战略性风险投资(通过 BioOne Capital 基金)和公共研究经费(通过后来成为 ASTAR 生物医学研究理事会的机构)(NAS,访问于 2026 年八月)。这一愿景是覆盖完整价值链——从基础研究到制造,再到医疗服务——而非仅将新加坡定位为低成本的药片压制生产地点。

Biopolis 于 2003 年十月在纬壹开园,定位为研究的基石:这是一个专门的生物医学研发园区,让公共研究机构与私人实验室汇聚一堂,以创造知识密集型就业岗位(NAS,访问于 2026 年八月)。与此同时,裕廊集团开发了大士生物医药园,作为相应的制造业园区。外国制药企业自 1970年代起就在新加坡设厂,但 2000 年启动的计划加快了产业向价值链上游发展,进入生物制品、活性药物成分和区域总部职能领域。这一模式体现了新加坡更广泛的发展方式:裕廊集团提供土地和基础设施,A*STAR 推动研究成果转化,EDB 促进投资,HSA 负责采用获国际认可的监管标准。

大士生物医药园制造业

位于新加坡西部的大士生物医药园(TBP)是制药、生物制品和医疗技术的主要制造园区。裕廊集团将 TBP 定位为即插即用型生物医药中心,配备专门建设的基础设施,包括电力、供水、排污、燃气、电信,以及蒸汽、冷冻水和废物处理等共用设施,使企业能够快速投产(裕廊集团,访问于 2026 年八月)。该园区由大士生物医药园 I(约 183 公顷)和大士生物医药园 II(约 188 公顷)组成,邻近通往马来西亚的大士关卡和正在建设中的大士港(裕廊集团,访问于 2026 年八月)。

多家全球大型生物制药制造商在 TBP 营运,包括议会答复中列出的 Pfizer、Novartis、GSK、Roche 和 MSD(贸工部,访问于 2026 年八月)。例如,GSK 位于大士的疫苗生产厂生产的两种疫苗覆盖全球约 45% 的儿童死亡致病原因;GSK 在新加坡的制药和疫苗业务共有约 1,600 名员工(裕廊集团,访问于 2026 年八月)。制造活动涵盖活性药物成分和最终剂型(包括注射剂)、生物制品、医疗器械,以及细胞处理等新兴能力。

裕廊集团还建设了支持性基础设施,例如 TBP 内的 JTC BioMed Hub,汇聚生物医学供应商和中小企业;以及由政府机构和主要设于园区的制药公司组成的生物制药产业理事会,以推动卓越制造。近期的主要投资包括 AstraZeneca 在大士南部投资 US$1.5 十亿美元建设抗体药物偶联物(ADC)端到端制造设施——这是该公司首个在同一园区涵盖原料药和制剂生产的全球 ADC 厂区,目标是在 2029 年前具备运营条件,并创造 800 多个就业岗位,从投产第一天起实现净零排放(贸工部,访问于 2026 年八月;EDB,访问于 2026 年八月)。

研究、创新与人才

新加坡的生物医学研究基础设施集中于纬壹,ASTAR 生物医学研究机构与企业实验室均设于 Biopolis。ASTAR 的生物医学机构包括生物信息学研究院、生物工艺技术研究院、新加坡基因组研究院、分子与细胞生物学研究院、新加坡免疫学网络,以及其他专注于传染病、食品和生物技术等领域的机构(A*STAR,访问于 2026 年八月)。Biopolis 的设计旨在让公共研究机构与产业共址——早期入驻机构包括诺华热带病研究所和约翰霍普金斯新加坡中心,A*STAR 研究所则从 2003 年起陆续迁入(NAS,访问于 2026 年八月)。EDB 表示,截至 2025 年,纬壹更广泛的园区内有 400 多家公司、15 个研究机构和 六所高等教育学府(EDB,访问于 2026 年八月)。

A*STAR 是研究成果转化的核心机构,通过产业合作和核酸疗法计划等国家级平台,将发现转化为应用(EDB,访问于 2026 年八月)。EDB 也开展海外培训计划,让新加坡毕业生先到跨国公司的制造厂工作,再返回本地工厂。截至 2025 年,新加坡报告的全国研究人员人数超过 53,000 人;工艺教育学院、理工学院和大学毕业生中,约 45% 来自 STEM 相关课程(EDB,访问于 2026 年八月)。生物制品、细胞与基因疗法、数字医疗和精准医疗等领域预计将成为该领域的下一个增长方向,并需要兼具临床专业知识与数据和计算技能的人才(EDB,访问于 2026 年八月)。

监管与制造标准

新加坡的药品制造由卫生科学局(HSA)监管;HSA 不同于由卫生部(MOH)主管的临床医疗保健系统,MOH 的临床医疗职责与 HSA 的工厂许可职责相互独立。HSA 的 GMP 许可涵盖治疗产品和活性成分的本地制造商;这些制造商必须遵守现行药品检查合作计划(PIC/S)《药品优良制造规范指南》(GMP)——这是确保生产和质量控制一致的国际标准(HSA,访问于 2026 年八月)。本地制造商必须通过 HSA 的许可前 GMP 审计,才能获得制造商执照;之后还会接受例行和突击审计(HSA,访问于 2026 年八月)。每个持牌厂区都必须为生产和质量运营指定具备相关实践经验的负责人(HSA,访问于 2026 年八月)。

HSA 加入 PIC/S,使新加坡制造的药品在全球供应链中更具公信力:海外监管机构在产品注册时接受 PIC/S 成员监管机构出具的 GMP 证明。HSA 鼓励计划在新加坡设立新制造厂区的企业,在设计过程中尽早联系其 GMP 部门(HSA,访问于 2026 年八月)。这种监管声誉与基础设施、人才和知识产权保护一同构成新加坡吸引投资的优势,使其能够发展高价值生物制品和 ADC 生产,而不只生产普通仿制药。

战略取舍与关键问题

该领域有两种不同的成功衡量标准。产业政策视角会衡量出口价值、固定资产投资、监管公信力、高技能就业岗位,以及吸引下一代复杂制造平台的能力;国内效益视角则会追问,这些成果在多大程度上能增强本地企业、研究职业发展、关键供应品的韧性,以及公众获得相关药品或器械的机会。EDB 和贸工部的资料证明了第一类产出,但这些资料本身无法回答第二类分配或医疗保健问题(EDB,访问于 2026 年八月;贸工部,访问于 2026 年八月)。

此外还存在韧性与效率之间的取舍。将工厂、供应商、研究机构和跨国公司总部集中在一体化集群中,可以缩短开发与制造之间的衔接时间;但依赖全球公司的研发管线,意味着即使新加坡的基本面保持强劲,厂区关闭或产品周期变化仍可能影响产出(裕廊集团,访问于 2026 年八月;贸工部,访问于 2026 年八月)。HSA 的 GMP 和许可标准有助于保障质量和供应链公信力,但合规、土地、人才和运营成本也都是竞争力方程的一部分(HSA,访问于 2026 年八月)。这些是评估问题,并非失败的证据:有关“韧性”、“本地能力”或“公共价值”的说法,应明确指标、时间段、对象群体和分母。

投资前景与行业挑战

EDB 在 2025 年为生物医学科学领域吸引了 S$4.4 十亿新元的固定资产投资,预计将在 五年内创造 1,775 个就业岗位(贸工部,访问于 2026 年八月)。政府称该领域前景强劲,并以 AstraZeneca 的 ADC 工厂等主要项目为例,说明新加坡仍能吸引复杂制造能力(贸工部,访问于 2026 年八月)。

该领域也面临阻力。2026 年五月,在本地生物制药工厂关闭消息公布后,议会提出质询,促使贸工部区分企业自身的商业决定与新加坡整体价值优势的减弱(贸工部,访问于 2026 年八月)。运营成本上升,以及竞争司法管辖区的区域劳动力能力提升,也带来压力。政府的应对重点是推动现有制造商采用生产力提升措施、自动化、人工智能和机器人技术,同时继续投资于研究基础设施、监管质量和人才培养渠道等基本条件(贸工部,访问于 2026 年八月)。对新加坡而言,生物医学科学领域仍是一项押注:这个没有国内市场的城邦能否凭借可信赖的监管、研究到工厂的一体化基础设施,以及掌握生物制品和精准医疗前沿技术的熟练劳动力,维持高端制造业优势。